A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and
safety of QL1706 in patients with recurrent or metastatic cervical cancer.